MXL non-prescription supplement: clinically proven to delay Alzheimers symptoms and improve memory

About MXLTM

Introducing a new intervention for Alzheimer's patients

There is now a non-prescription option for improving cognition and calming anxiety. MXL was proven effective in several clinical studies, described briefly below. For more details, see the Clinical Results page on this website.

MXL (Patent Pending) was developed at a major U.S. University.

Clinical trials demonstrate that MXL helps persons with early-stage Alzheimer's disease feel better, function better and communicate better.

Clinical trials also show that MXL improves recall and mental alertness in people without dementia.

MXL is a combination of 6 vitamins and nutritional factors that provides antioxidant protection and energy for brain cells.

Laboratory tests show that MXL increases production of an essential neurotransmitter, acetylcholine, which allows brain cells to transmit signals for thoughts and memories.

Is it Alzheimer's disease?

The earliest indications of cognitive decline are elusive. Some decline can accompany normal aging or may indicate Mild Cognitive Impairment (MCI), which often leads to Alzheimer's disease1. There is no effective medication at this stage2.

MXL, a non-prescription nutritional supplement, improves recall and memory in adults prior to any diagnosis of dementia.

Treatment can be initiated at the first indication of memory dysfunction, or even before any loss. There is no need to wait until cognitive decline is severe enough to warrant a diagnosis of Alzheimer's disease.

When it is Alzheimer's disease

MXL can maintain and even increase cognitive performance as well as reduce agitation and irritation, for as long as two years in mild to moderate Alzheimer's disease3 and for six months when treatment was initiated in late-state Alzheimer's disease4. MXL fights the long-term ravages of Alzheimer's disease and normal aging.

The components of MXL:

  • Reduce production of beta amyloid (which forms senile plaques)5
  • Reduce production of phosphor-tau (which forms neurofibrillary tangles)6
  • Reduce levels of homocysteine (which imparts oxidative damage to brain cells)7
  • Maintain levels of the cognitive neurotransmitter acetylcholine8

MXL may therefore be an important addition to ongoing cholinesterase inhibitor therapy9

Who should take MXL?

  • Those with Alzheimer's disease
  • Those with dementia and/or mild cognitive impairment
  • Healthy people of all ages desiring to improve neurological functions and memory
  1. Teng et al. EGenatr Cogn Disord. 2007;24:253
  2. Bikr & Flicker Coch Database Syst. Rev. 2006 3:CD006104
  3. Chan et al. Am J Alz Dis Other Dementias: In press
  4. Remington et al. Submitted Am J Alz Dis Other Dementias
  5. Chan & Shea. J Neurochem 2007; 102:753
  6. Chan & Shea. J Alz dis 2006; 9:399
  7. Dhitavat et al. Brain Res 2005; 9:114
  8. Chan et al. J Health Nutr Aging 2008; 12:252
  9. Connelly et al. Int J Geriatr Psychiatry 2008; 23:155